Cell Genesys Halts VITAL-2 GVAX Trial in Advanced Prostate Cancer

August 27th, 2008 by David

Aug 27, 2008 - Cell Genesys, Inc. today announced that it has terminated VITAL-2, the second of two Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, which compares GVAX immunotherapy in ...